Evidence map›Paper›PMID 27983532›Full record

ArticleCancer biomarkers : section A of Disease markers2017

MN1 and PTEN gene expression in acute myeloid leukemia.

Rania A Zayed, Maha A Eltaweel, Shahira K A Botros, Mohamed A Zaki

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Cancer resistance via the downregulation of the tumor suppressorsExploration of targeted anti-tumor therapy · 2023
    Review
  4. Review
  5. Cancer management and research · 2020
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rania A ZayedClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Maha A EltaweelClinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Shahira K A BotrosClinical and Chemical Pathology Department, Faculty of Medicine, Cairo University, Giza, Egypt.
Mohamed A ZakiClinical and Chemical Pathology Department, National Cancer Institute, Cairo University, Giza, Egypt.
Cairo University · EGGTx (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMultiple genetic alterations with prognostic significance have been discovered in acute myeloid leukemia (AML). We studied the expression level of two genes, Meningioma1 (MN1) and Phosphatase and Tensin homolog (PTEN) to determine their expression in AML patients and their role as prognostic markers.

methodsThe study included 50 cytogenetic normal de novo AML cases and 10 controls, Their level was detected by Real time Reverse Transcription-Polymerase Chain Reaction.

resultRelative mRNA expression of MN1 was significantly higher (p value < 0.001) and PTEN expression was significantly lower (p value = 0.002). No correlation was found between neither MN1 nor PTEN mRNA expression and overall survival (p value = 0.212 and 0.310) respectively.

conclusionAlthough our study suggests a role for MN1 gene and PTEN genes in AML, we could not recommend their use as routine diagnostic and prognostic markers for AML in Egyptian population.

Indexed as

AdolescentAdultAgedCase-Control StudiesFemaleGene Expression Regulation, LeukemicHumansLeukemia, Myeloid, AcuteMaleMiddle AgedPTEN PhosphohydrolaseTrans-ActivatorsTumor Suppressor ProteinsYoung AdultMN1 protein, humanPTEN PhosphohydrolasePTEN protein, humanTrans-ActivatorsTumor Suppressor ProteinsAMLMN1PCRPROGNOSISPTEN

Identifiers

PMID27983532
PMCPMC13020580
OpenAlexW2561752776

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.